{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,11]],"date-time":"2026-11-11T21:49:10Z","timestamp":1794433750515,"version":"4.9.1"},"reference-count":50,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,6,26]],"date-time":"2024-06-26T00:00:00Z","timestamp":1719360000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,6,26]],"date-time":"2024-06-26T00:00:00Z","timestamp":1719360000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100004587","name":"Instituto de Salud Carlos III","doi-asserted-by":"publisher","award":["Rio Hortega"],"award-info":[{"award-number":["Rio Hortega"]}],"id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004587","name":"Instituto de Salud Carlos III","doi-asserted-by":"publisher","award":["Rio Hortega"],"award-info":[{"award-number":["Rio Hortega"]}],"id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004587","name":"Instituto de Salud Carlos III","doi-asserted-by":"publisher","award":["Rio Hortega"],"award-info":[{"award-number":["Rio Hortega"]}],"id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004587","name":"Instituto de Salud Carlos III","doi-asserted-by":"publisher","award":["PI18\/00335 to MCI"],"award-info":[{"award-number":["PI18\/00335 to MCI"]}],"id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004587","name":"Instituto de Salud Carlos III","doi-asserted-by":"publisher","award":["Juan Rod\u00e9s Contract (JR20\/0018)"],"award-info":[{"award-number":["Juan Rod\u00e9s Contract (JR20\/0018)"]}],"id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004587","name":"Instituto de Salud Carlos III","doi-asserted-by":"publisher","award":["Juan Rod\u00e9s contract JR18-00018; Fondo de investigaci\u00f3n sanitaria grant PI19\/00882"],"award-info":[{"award-number":["Juan Rod\u00e9s contract JR18-00018; Fondo de investigaci\u00f3n sanitaria grant PI19\/00882"]}],"id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004587","name":"Instituto de Salud Carlos III","doi-asserted-by":"publisher","award":["PI14\/01126, PI17\/01019 and PI20\/01473 to JF"],"award-info":[{"award-number":["PI14\/01126, PI17\/01019 and PI20\/01473 to JF"]}],"id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004587","name":"Instituto de Salud Carlos III","doi-asserted-by":"publisher","award":["PI17\/01896 and AC19\/00103to AL"],"award-info":[{"award-number":["PI17\/01896 and AC19\/00103to AL"]}],"id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004587","name":"Instituto de Salud Carlos III","doi-asserted-by":"publisher","award":["PI18\/00164; PI21\/00140"],"award-info":[{"award-number":["PI18\/00164; PI21\/00140"]}],"id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004587","name":"Instituto de Salud Carlos III","doi-asserted-by":"publisher","award":["PI18\/00435 and INT19\/00016"],"award-info":[{"award-number":["PI18\/00435 and INT19\/00016"]}],"id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100015442","name":"Global Brain Health Institute","doi-asserted-by":"publisher","award":["Atlantic Fellows for Equity in Brain Health at the Global Brain Health Institute"],"award-info":[{"award-number":["Atlantic Fellows for Equity in Brain Health at the Global Brain Health Institute"]}],"id":[{"id":"10.13039\/100015442","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000957","name":"Alzheimer\u2019s Association","doi-asserted-by":"crossref","award":["ALZ UK-21-720973"],"award-info":[{"award-number":["ALZ UK-21-720973"]}],"id":[{"id":"10.13039\/100000957","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100017506","name":"Alzheimer\u2019s Society","doi-asserted-by":"publisher","award":["AACSF-21-850193"],"award-info":[{"award-number":["AACSF-21-850193"]}],"id":[{"id":"10.13039\/501100017506","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000957","name":"Alzheimer's Association","doi-asserted-by":"publisher","award":["Alzheimer\u2019s Association clinician scientist fellowship (AACSF-22-972945)"],"award-info":[{"award-number":["Alzheimer\u2019s Association clinician scientist fellowship (AACSF-22-972945)"]}],"id":[{"id":"10.13039\/100000957","id-type":"DOI","asserted-by":"publisher"}]},{"name":"NIH","award":["National Institutes of Health (R01AG080470)"],"award-info":[{"award-number":["National Institutes of Health (R01AG080470)"]}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"crossref","award":["NIA grants 1R01AG056850-01A1; R21AG056974; and R01AG061566 to JF"],"award-info":[{"award-number":["NIA grants 1R01AG056850-01A1; R21AG056974; and R01AG061566 to JF"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100008666","name":"Fundaci\u00f3 la Marat\u00f3 de TV3","doi-asserted-by":"publisher","award":["20141210 to JF"],"award-info":[{"award-number":["20141210 to JF"]}],"id":[{"id":"10.13039\/100008666","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008666","name":"Fundaci\u00f3 la Marat\u00f3 de TV3","doi-asserted-by":"publisher","award":["20142610 to AL"],"award-info":[{"award-number":["20142610 to AL"]}],"id":[{"id":"10.13039\/100008666","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Pla Estrat\u00e8gic de Recerca i Innovaci\u00f3 en Salut"},{"DOI":"10.13039\/501100015496","name":"Centro de Investigaci\u00f3n Biom\u00e9dica en Red sobre Enfermedades Neurodegenerativas","doi-asserted-by":"publisher","award":["Program 1, Alzheimer Disease to AL"],"award-info":[{"award-number":["Program 1, Alzheimer Disease to AL"]}],"id":[{"id":"10.13039\/501100015496","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002809","name":"Generalitat de Catalunya","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100002809","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Fundaci\u00f3n Tatiana","id":[{"id":"https:\/\/ror.org\/01mzzkz08","id-type":"ROR","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100008530","name":"Fondo Europeo de Desarrollo Regional","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100008530","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Pla Estrat\u00e8gic de Recerca i Innovaci\u00f3 en Salut","award":["PERIS SLT006\/17\/125"],"award-info":[{"award-number":["PERIS SLT006\/17\/125"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Alz Res Therapy"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Recently developed blood markers for Alzheimer's disease (AD) detection have high accuracy but usually require ultra-sensitive analytic tools not commonly available in clinical laboratories, and their performance in clinical practice is unknown.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      We analyzed plasma samples from 290 consecutive participants that underwent lumbar puncture in routine clinical practice in a specialized memory clinic (66 cognitively unimpaired, 130 participants with mild cognitive impairment, and 94 with dementia). Participants were classified as amyloid positive (A\u2009+) or negative (A-) according to CSF A\u03b2\n                      <jats:sub>1\u201342<\/jats:sub>\n                      \/A\u03b2\n                      <jats:sub>1\u201340<\/jats:sub>\n                      ratio. Plasma pTau\n                      <jats:sub>217<\/jats:sub>\n                      , pTau\n                      <jats:sub>181<\/jats:sub>\n                      , A\u03b2\n                      <jats:sub>1\u201342<\/jats:sub>\n                      and A\u03b2\n                      <jats:sub>1\u201340<\/jats:sub>\n                      were measured in the fully-automated LUMIPULSE platform. We used linear regression to compare plasma biomarkers concentrations between A\u2009+\u2009and A- groups, evaluated Spearman\u2019s correlation between plasma and CSF and performed ROC analyses to assess their diagnostic accuracy to detect brain amyloidosis as determined by CSF A\u03b2\n                      <jats:sub>1\u201342<\/jats:sub>\n                      \/A\u03b2\n                      <jats:sub>1\u201340<\/jats:sub>\n                      ratio. We analyzed the concordance of pTau\n                      <jats:sub>217<\/jats:sub>\n                      with CSF amyloidosis.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Plasma pTau\n                      <jats:sub>217<\/jats:sub>\n                      and pTau\n                      <jats:sub>181<\/jats:sub>\n                      concentration were higher in A\u2009+\u2009than A- while the plasma A\u03b2\n                      <jats:sub>1\u201342<\/jats:sub>\n                      \/A\u03b2\n                      <jats:sub>1\u201340<\/jats:sub>\n                      ratio was lower in A\u2009+\u2009compared to A-. pTau\n                      <jats:sub>181<\/jats:sub>\n                      and the A\u03b2\n                      <jats:sub>1\u201342<\/jats:sub>\n                      \/A\u03b2\n                      <jats:sub>1\u201340<\/jats:sub>\n                      ratio showed moderate correlation between plasma and CSF (Rho\u2009=\u20090.66 and 0.69, respectively). The areas under the ROC curve to discriminate A\u2009+\u2009from A- participants were 0.94 (95% CI 0.92\u20130.97) for pTau\n                      <jats:sub>217<\/jats:sub>\n                      , and 0.88 (95% CI 0.84\u20130.92) for both pTau\n                      <jats:sub>181<\/jats:sub>\n                      and A\u03b2\n                      <jats:sub>1\u201342<\/jats:sub>\n                      \/A\u03b2\n                      <jats:sub>1\u201340<\/jats:sub>\n                      . Chronic kidney disease (CKD) was related to increased plasma biomarker concentrations, but ratios were less affected. Plasma pTau\n                      <jats:sub>217<\/jats:sub>\n                      had the highest fold change (\u00d7\u20093.2) and showed high predictive capability in discriminating A\u2009+\u2009from A-, having 4\u20137% misclassification rate. The global accuracy of plasma pTau\n                      <jats:sub>217<\/jats:sub>\n                      using a two-threshold approach was robust in symptomatic groups, exceeding 90%.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>\n                      The evaluation of blood biomarkers on an automated platform exhibited high diagnostic accuracy for AD pathophysiology, and pTau\n                      <jats:sub>217<\/jats:sub>\n                      showed excellent diagnostic accuracy to identify participants with AD in a consecutive sample representing the routine clinical practice in a specialized memory unit.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s13195-024-01513-9","type":"journal-article","created":{"date-parts":[[2024,6,26]],"date-time":"2024-06-26T05:03:37Z","timestamp":1719378217000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":150,"title":["Diagnostic performance of plasma pTau217, pTau181, A\u03b21-42 and A\u03b21-40 in the LUMIPULSE automated platform for the detection of Alzheimer disease"],"prefix":"10.1186","volume":"16","author":[{"given":"Javier","family":"Arranz","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nuole","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara","family":"Rubio-Guerra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"\u00cd\u00f1igo","family":"Rodr\u00edguez-Baz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rosa","family":"Ferrer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mar\u00eda","family":"Carmona-Iragui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isabel","family":"Barroeta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ignacio","family":"Ill\u00e1n-Gala","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miguel","family":"Santos-Santos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan","family":"Fortea","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alberto","family":"Lle\u00f3","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mireia","family":"Tondo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Alcolea","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,6,26]]},"reference":[{"key":"1513_CR1","doi-asserted-by":"publisher","first-page":"1113","DOI":"10.1016\/j.jalz.2016.10.001","volume":"12","author":"KN Fargo","year":"2016","unstructured":"Fargo KN, Carrillo MC, Weiner MW, et al. The crisis in recruitment for clinical trials in Alzheimer\u2019s and dementia: An action plan for solutions. Alzheimer\u2019s and Dementia. 2016;12:1113\u20135. https:\/\/doi.org\/10.1016\/j.jalz.2016.10.001.","journal-title":"Alzheimer\u2019s and Dementia"},{"key":"1513_CR2","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1016\/S1474-4422(21)00361-6","volume":"21","author":"CE Teunissen","year":"2022","unstructured":"Teunissen CE, Verberk IMW, Thijssen EH, et al. Blood-based biomarkers for Alzheimer\u2019s disease: towards clinical implementation. Lancet Neurol. 2022;21:66\u201377. https:\/\/doi.org\/10.1016\/S1474-4422(21)00361-6.","journal-title":"Lancet Neurol"},{"key":"1513_CR3","doi-asserted-by":"publisher","first-page":"1206","DOI":"10.1136\/jnnp-2021-326603","volume":"92","author":"D Alcolea","year":"2021","unstructured":"Alcolea D, Delaby C, Mu\u00f1oz L, et al. Use of plasma biomarkers for AT(N) classification of neurodegenerative dementias. J Neurol Neurosurg Psychiatry. 2021;92:1206\u201314.","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"1513_CR4","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000207193","author":"D Alcolea","year":"2023","unstructured":"Alcolea D, Beeri MS, Rojas JC, et al. Blood Biomarkers in Neurodegenerative Diseases: Implications for the Clinical Neurologist. Neurology. 2023. https:\/\/doi.org\/10.1212\/WNL.0000000000207193.","journal-title":"Neurology"},{"key":"1513_CR5","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1038\/nature25456","volume":"554","author":"A Nakamura","year":"2018","unstructured":"Nakamura A, Kaneko N, Villemagne VL, et al. High performance plasma amyloid-\u03b2 biomarkers for Alzheimer\u2019s disease. Nature. 2018;554:249\u201354.","journal-title":"Nature"},{"key":"1513_CR6","doi-asserted-by":"publisher","unstructured":"Janelidze S, Stomrud E, Palmqvist S, et al. Plasma \u03b2-amyloid in Alzheimer\u2019s disease and vascular disease. Sci Rep. 2016;6. https:\/\/doi.org\/10.1038\/srep26801.","DOI":"10.1038\/srep26801"},{"key":"1513_CR7","doi-asserted-by":"publisher","DOI":"10.1002\/alz.12841","author":"NJ Ashton","year":"2022","unstructured":"Ashton NJ, Puig-Pijoan A, Mil\u00e0-Alom\u00e0 M, et al. Plasma and CSF biomarkers in a memory clinic: Head-to-head comparison of phosphorylated tau immunoassays. Alzheimer\u2019s Dement Published Online First. 2022. https:\/\/doi.org\/10.1002\/alz.12841.","journal-title":"Alzheimer\u2019s Dement"},{"key":"1513_CR8","doi-asserted-by":"publisher","first-page":"E1647","DOI":"10.1212\/WNL.0000000000008081","volume":"93","author":"SE Schindler","year":"2019","unstructured":"Schindler SE, Bollinger JG, Ovod V, et al. High-precision plasma \u03b2-amyloid 42\/40 predicts current and future brain amyloidosis. Neurology. 2019;93:E1647\u201359.","journal-title":"Neurology"},{"key":"1513_CR9","doi-asserted-by":"publisher","unstructured":"Montoliu-Gaya L, Strydom A, Blennow K, et al. Blood biomarkers for alzheimer\u2019s disease in down syndrome. J Clin Med. 2021;10. https:\/\/doi.org\/10.3390\/jcm10163639.","DOI":"10.3390\/jcm10163639"},{"key":"1513_CR10","doi-asserted-by":"publisher","first-page":"1375","DOI":"10.1001\/jamaneurol.2021.3180","volume":"78","author":"S Janelidze","year":"2021","unstructured":"Janelidze S, Teunissen CE, Zetterberg H, et al. Head-to-Head Comparison of 8 Plasma Amyloid-\u03b2 42\/40 Assays in Alzheimer Disease. JAMA Neurol. 2021;78:1375\u201382.","journal-title":"JAMA Neurol"},{"key":"1513_CR11","doi-asserted-by":"publisher","unstructured":"Bayoumy S, Verberk IMW, den Dulk B, et al. Clinical and analytical comparison of six Simoa assays for plasma P-tau isoforms P-tau181, P-tau217, and P-tau231. Alzheimers Res Ther. 2021;13. https:\/\/doi.org\/10.1186\/s13195-021-00939-9.","DOI":"10.1186\/s13195-021-00939-9"},{"key":"1513_CR12","doi-asserted-by":"publisher","first-page":"e671","DOI":"10.1212\/WNL.0000000000011226","volume":"96","author":"I Ill\u00e1n-Gala","year":"2021","unstructured":"Ill\u00e1n-Gala I, Lleo A, Karydas A, et al. Plasma Tau and Neurofilament Light in Frontotemporal Lobar Degeneration and Alzheimer Disease. Neurology. 2021;96:e671\u201383.","journal-title":"Neurology"},{"key":"1513_CR13","doi-asserted-by":"publisher","first-page":"1398","DOI":"10.1038\/s41591-022-01822-2","volume":"28","author":"MM Mielke","year":"2022","unstructured":"Mielke MM, Dage JL, Frank RD, et al. Performance of plasma phosphorylated tau 181 and 217 in the community. Nat Med. 2022;28:1398\u2013405.","journal-title":"Nat Med"},{"key":"1513_CR14","doi-asserted-by":"publisher","DOI":"10.1002\/alz.12787","author":"A Pichet Binette","year":"2022","unstructured":"Pichet Binette A, Janelidze S, Cullen N, et al. Confounding factors of Alzheimer\u2019s disease plasma biomarkers and their impact on clinical performance. Alzheimer\u2019s and Dementia Published Online First. 2022. https:\/\/doi.org\/10.1002\/alz.12787.","journal-title":"Alzheimer\u2019s and Dementia Published Online First"},{"key":"1513_CR15","doi-asserted-by":"publisher","first-page":"1128","DOI":"10.1002\/alz.12466","volume":"18","author":"JA Syrjanen","year":"2022","unstructured":"Syrjanen JA, Campbell MR, Algeciras-Schimnich A, et al. Associations of amyloid and neurodegeneration plasma biomarkers with comorbidities. Alzheimer\u2019s Dement. 2022;18:1128\u201340.","journal-title":"Alzheimer\u2019s Dement"},{"key":"1513_CR16","doi-asserted-by":"publisher","first-page":"2555","DOI":"10.1038\/s41591-022-02074-w","volume":"28","author":"NJ Ashton","year":"2022","unstructured":"Ashton NJ, Janelidze S, Mattsson-Carlgren N, et al. Differential roles of A\u03b242\/40, p-tau231 and p-tau217 for Alzheimer\u2019s trial selection and disease monitoring. Nat Med. 2022;28:2555\u201362.","journal-title":"Nat Med"},{"key":"1513_CR17","doi-asserted-by":"publisher","first-page":"648","DOI":"10.1002\/ana.25334","volume":"84","author":"IMW Verberk","year":"2018","unstructured":"Verberk IMW, Slot RE, Verfaillie SCJ, et al. Plasma Amyloid as Prescreener for the Earliest Alzheimer Pathological Changes. Ann Neurol. 2018;84:648\u201358.","journal-title":"Ann Neurol"},{"key":"1513_CR18","doi-asserted-by":"publisher","unstructured":"Pichet Binette A, Palmqvist S, Bali D, et al. Combining plasma phospho-tau and accessible measures to evaluate progression to Alzheimer\u2019s dementia in mild cognitive impairment patients. Alzheimers Res Ther. 2022;14. https:\/\/doi.org\/10.1186\/s13195-022-00990-0.","DOI":"10.1186\/s13195-022-00990-0"},{"key":"1513_CR19","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-021-01348-z","author":"S Palmqvist","year":"2021","unstructured":"Palmqvist S, Tideman P, Cullen N, et al. Prediction of future Alzheimer\u2019s disease dementia using plasma phospho-tau combined with other accessible measures. Nat Med Published Online First. 2021. https:\/\/doi.org\/10.1038\/s41591-021-01348-z.","journal-title":"Nat Med Published Online First"},{"key":"1513_CR20","doi-asserted-by":"publisher","first-page":"360","DOI":"10.1001\/jamaneurol.2022.5272","volume":"80","author":"N Mattsson-Carlgren","year":"2023","unstructured":"Mattsson-Carlgren N, Salvad\u00f3 G, Ashton NJ, et al. Prediction of Longitudinal Cognitive Decline in Preclinical Alzheimer Disease Using Plasma Biomarkers. JAMA Neurol. 2023;80:360\u20139.","journal-title":"JAMA Neurol"},{"key":"1513_CR21","doi-asserted-by":"publisher","first-page":"3170","DOI":"10.1093\/BRAIN\/AWAA329","volume":"143","author":"CE Teunissen","year":"2020","unstructured":"Teunissen CE, Thijssen EH. Plasma p-tau217: From \u2018new kid\u2019 to most promising candidate for Alzheimer\u2019s disease blood test. Brain. 2020;143:3170\u201380. https:\/\/doi.org\/10.1093\/BRAIN\/AWAA329.","journal-title":"Brain"},{"key":"1513_CR22","doi-asserted-by":"publisher","unstructured":"Salvad\u00f3 G, Ossenkoppele R, Ashton NJ, et al. Specific associations between plasma biomarkers and postmortem amyloid plaque and tau tangle loads. EMBO Mol Med. 2023;15. https:\/\/doi.org\/10.15252\/emmm.202217123.","DOI":"10.15252\/emmm.202217123"},{"key":"1513_CR23","doi-asserted-by":"publisher","unstructured":"Janelidze S, Bali D, Ashton NJ, et al. Head-to-head comparison of 10 plasma phospho-tau assays in prodromal Alzheimer\u2019s disease. Brain. Published Online First. 2022. https:\/\/doi.org\/10.1093\/brain\/awac333.","DOI":"10.1093\/brain\/awac333"},{"key":"1513_CR24","doi-asserted-by":"publisher","unstructured":"Ashton NJ, Brum WS, Di Molfetta G, et al. Diagnostic accuracy of the plasma ALZpath pTau217 immunoassay to identify Alzheimer\u2019s disease pathology. medRxiv. Published Online First: 12 July 2023. https:\/\/doi.org\/10.1101\/2023.07.11.23292493.","DOI":"10.1101\/2023.07.11.23292493"},{"key":"1513_CR25","doi-asserted-by":"publisher","first-page":"797","DOI":"10.1002\/alz.12706","volume":"19","author":"NC Cullen","year":"2023","unstructured":"Cullen NC, Janelidze S, Mattsson-Carlgren N, et al. Test-retest variability of plasma biomarkers in Alzheimer\u2019s disease and its effects on clinical prediction models. Alzheimer\u2019s Dement. 2023;19:797\u2013806.","journal-title":"Alzheimer\u2019s Dement"},{"key":"1513_CR26","first-page":"1797","volume":"28","author":"M Mil\u00e0-Alom\u00e0","year":"2022","unstructured":"Mil\u00e0-Alom\u00e0 M, Ashton NJ, Shekari M, et al. Plasma p-tau231 and p-tau217 as state markers of amyloid-\u03b2 pathology in preclinical Alzheimer\u2019s disease. Nat Med. 2022;28:1797\u2013801.","journal-title":"Nat Med"},{"key":"1513_CR27","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s00401-023-02570-4","volume":"146","author":"L Yu","year":"2023","unstructured":"Yu L, Boyle PA, Janelidze S, et al. Plasma p-tau181 and p-tau217 in discriminating PART, AD and other key neuropathologies in older adults. Acta Neuropathol. 2023;146:1\u201311.","journal-title":"Acta Neuropathol"},{"key":"1513_CR28","doi-asserted-by":"publisher","first-page":"355","DOI":"10.3233\/ADR-230029","volume":"7","author":"MV Pais","year":"2023","unstructured":"Pais MV, Forlenza OV, Diniz BS. Plasma Biomarkers of Alzheimer\u2019s Disease: A Review of Available Assays, Recent Developments, and Implications for Clinical Practice. J Alzheimers Dis Rep. 2023;7:355\u201380.","journal-title":"J Alzheimers Dis Rep"},{"key":"1513_CR29","doi-asserted-by":"publisher","first-page":"2029","DOI":"10.1093\/brain\/awad042","volume":"146","author":"CR Jack","year":"2023","unstructured":"Jack CR, Wiste HJ, Algeciras-Schimnich A, et al. Predicting amyloid PET and tau PET stages with plasma biomarkers. Brain. 2023;146:2029\u201344.","journal-title":"Brain"},{"key":"1513_CR30","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1001\/jamaneurol.2022.4485","volume":"80","author":"J Therriault","year":"2023","unstructured":"Therriault J, Vermeiren M, Servaes S, et al. Association of Phosphorylated Tau Biomarkers with Amyloid Positron Emission Tomography vs Tau Positron Emission Tomography. JAMA Neurol. 2023;80:188\u201399.","journal-title":"JAMA Neurol"},{"key":"1513_CR31","doi-asserted-by":"publisher","DOI":"10.1002\/alz.13026","author":"J Therriault","year":"2023","unstructured":"Therriault J, Servaes S, Tissot C, et al. Equivalence of plasma p-tau217 with cerebrospinal fluid in the diagnosis of Alzheimer\u2019s disease. Alzheimer\u2019s Dement Published Online First. 2023. https:\/\/doi.org\/10.1002\/alz.13026.","journal-title":"Alzheimer\u2019s Dement Published Online First"},{"key":"1513_CR32","doi-asserted-by":"publisher","unstructured":"Groot C, Cicognola C, Bali D, et al. Diagnostic and prognostic performance to detect Alzheimer\u2019s disease and clinical progression of a novel assay for plasma p-tau217. Alzheimers Res Ther. 2022;14. https:\/\/doi.org\/10.1186\/s13195-022-01005-8.","DOI":"10.1186\/s13195-022-01005-8"},{"key":"1513_CR33","doi-asserted-by":"publisher","first-page":"772","DOI":"10.1001\/jama.2020.12134","volume":"324","author":"S Palmqvist","year":"2020","unstructured":"Palmqvist S, Janelidze S, Quiroz YT, et al. Discriminative Accuracy of Plasma Phospho-tau217 for Alzheimer Disease vs Other Neurodegenerative Disorders. J Am M Assoc. 2020;324:772\u201381.","journal-title":"J Am M Assoc"},{"key":"1513_CR34","doi-asserted-by":"publisher","first-page":"2669","DOI":"10.1002\/alz.12756","volume":"18","author":"O Hansson","year":"2022","unstructured":"Hansson O, Edelmayer RM, Boxer AL, et al. The Alzheimer\u2019s Association appropriate use recommendations for blood biomarkers in Alzheimer\u2019s disease. Alzheimer\u2019s Dement. 2022;18:2669\u201386. https:\/\/doi.org\/10.1002\/alz.12756.","journal-title":"Alzheimer\u2019s Dement"},{"key":"1513_CR35","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1016\/j.trci.2019.09.005","volume":"5","author":"D Alcolea","year":"2019","unstructured":"Alcolea D, Clarim\u00f3n J, Carmona-Iragui M, et al. The Sant Pau Initiative on Neurodegeneration (SPIN) cohort: a data set for biomarker discovery and validation in neurodegenerative disorders. Alzheimer\u2019s Dement. 2019;5:597\u2013609.","journal-title":"Alzheimer\u2019s Dement"},{"key":"1513_CR36","doi-asserted-by":"publisher","first-page":"1580","DOI":"10.1515\/cclm-2023-0245","volume":"61","author":"A Mansilla","year":"2023","unstructured":"Mansilla A, Canyelles M, Ferrer R, et al. Effects of storage conditions on the stability of blood-based markers for the diagnosis of Alzheimer\u2019s disease. Clin Chem Lab Med. 2023;61:1580\u20139.","journal-title":"Clin Chem Lab Med"},{"key":"1513_CR37","doi-asserted-by":"publisher","first-page":"1815","DOI":"10.1002\/acn3.50873","volume":"6","author":"D Alcolea","year":"2019","unstructured":"Alcolea D, Pegueroles J, Mu\u00f1oz L, et al. Agreement of amyloid PET and CSF biomarkers for Alzheimer\u2019s disease on Lumipulse. Ann Clin Transl Neurol. 2019;6:1815\u201324.","journal-title":"Ann Clin Transl Neurol"},{"key":"1513_CR38","doi-asserted-by":"publisher","DOI":"10.1038\/s43587-023-00471-5","author":"WS Brum","year":"2023","unstructured":"Brum WS, Cullen NC, Janelidze S, et al. A two-step workflow based on plasma p-tau217 to screen for amyloid \u03b2 positivity with further confirmatory testing only in uncertain cases. Nat Aging Published Online First. 2023. https:\/\/doi.org\/10.1038\/s43587-023-00471-5.","journal-title":"Nat Aging Published Online First"},{"key":"1513_CR39","doi-asserted-by":"publisher","unstructured":"Baiardi S, Quadalti C, Mammana A, et al. Diagnostic value of plasma p-tau181, NfL, and GFAP in a clinical setting cohort of prevalent neurodegenerative dementias. Alzheimers Res Ther. 2022;14. https:\/\/doi.org\/10.1186\/s13195-022-01093-6.","DOI":"10.1186\/s13195-022-01093-6"},{"key":"1513_CR40","doi-asserted-by":"publisher","unstructured":"Wilson EN, Young CB, Ramos Benitez J, et al. Performance of a fully-automated Lumipulse plasma phospho-tau181 assay for Alzheimer\u2019s disease. Alzheimers Res Ther. 2022;14. https:\/\/doi.org\/10.1186\/s13195-022-01116-2.","DOI":"10.1186\/s13195-022-01116-2"},{"key":"1513_CR41","doi-asserted-by":"publisher","first-page":"739","DOI":"10.1016\/S1474-4422(21)00214-3","volume":"20","author":"EH Thijssen","year":"2021","unstructured":"Thijssen EH, La Joie R, Strom A, et al. Plasma phosphorylated tau 217 and phosphorylated tau 181 as biomarkers in Alzheimer\u2019s disease and frontotemporal lobar degeneration: a retrospective diagnostic performance study. Lancet Neurol. 2021;20:739\u201352.","journal-title":"Lancet Neurol"},{"key":"1513_CR42","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1016\/S1474-4422(20)30071-5","volume":"19","author":"TK Karikari","year":"2020","unstructured":"Karikari TK, Pascoal TA, Ashton NJ, et al. Blood phosphorylated tau 181 as a biomarker for Alzheimer\u2019s disease: a diagnostic performance and prediction modelling study using data from four prospective cohorts. Lancet Neurol. 2020;19:422\u201333.","journal-title":"Lancet Neurol"},{"key":"1513_CR43","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000201597","author":"J Sarto","year":"2022","unstructured":"Sarto J, Ruiz-Garc\u00eda R, Guill\u00e9n N, et al. Diagnostic Performance and Clinical Applicability of Blood-Based Biomarkers in a Prospective Memory Clinic Cohort. Neurology. 2022. https:\/\/doi.org\/10.1212\/WNL.0000000000201597.","journal-title":"Neurology"},{"key":"1513_CR44","doi-asserted-by":"publisher","first-page":"1353","DOI":"10.1002\/alz.12301","volume":"17","author":"AM Brickman","year":"2021","unstructured":"Brickman AM, Manly JJ, Honig LS, et al. Plasma p-tau181, p-tau217, and other blood-based Alzheimer\u2019s disease biomarkers in a multi-ethnic, community study. Alzheimer\u2019s and Dementia. 2021;17:1353\u201364.","journal-title":"Alzheimer\u2019s and Dementia"},{"key":"1513_CR45","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1038\/s43587-020-00003-5","volume":"1","author":"NC Cullen","year":"2021","unstructured":"Cullen NC, Leuzy A, Palmqvist S, et al. Individualized prognosis of cognitive decline and dementia in mild cognitive impairment based on plasma biomarker combinations. Nat Aging. 2021;1:114\u201323.","journal-title":"Nat Aging"},{"key":"1513_CR46","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1002\/alz.12395","volume":"18","author":"S Janelidze","year":"2022","unstructured":"Janelidze S, Palmqvist S, Leuzy A, et al. Detecting amyloid positivity in early Alzheimer\u2019s disease using combinations of plasma A\u03b242\/A\u03b240 and p-tau. Alzheimer\u2019s Dement. 2022;18:283\u201393.","journal-title":"Alzheimer\u2019s Dement"},{"key":"1513_CR47","doi-asserted-by":"publisher","first-page":"1204","DOI":"10.1002\/alz.12751","volume":"19","author":"S Palmqvist","year":"2023","unstructured":"Palmqvist S, Stomrud E, Cullen N, et al. An accurate fully automated panel of plasma biomarkers for Alzheimer\u2019s disease. Alzheimer\u2019s Dement. 2023;19:1204\u201315.","journal-title":"Alzheimer\u2019s Dement"},{"key":"1513_CR48","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1186\/s13195-023-01319-1","volume":"15","author":"F Mart\u00ednez-Dubarbie","year":"2023","unstructured":"Mart\u00ednez-Dubarbie F, Guerra-Ruiz A, L\u00f3pez-Garc\u00eda S, et al. Accuracy of plasma A\u03b240, A\u03b242, and p-tau181 to detect CSF Alzheimer\u2019s pathological changes in cognitively unimpaired subjects using the Lumipulse automated platform. Alzheimers Res Ther. 2023;15:163.","journal-title":"Alzheimers Res Ther"},{"key":"1513_CR49","doi-asserted-by":"publisher","first-page":"E53","DOI":"10.1515\/cclm-2022-0770","volume":"61","author":"G Musso","year":"2023","unstructured":"Musso G, Cosma C, Zaninotto M, et al. Pre-analytical variability of the Lumipulse immunoassay for plasma biomarkers of Alzheimer\u2019s disease. Clin Chem Lab Med. 2023;61:E53\u20136. https:\/\/doi.org\/10.1515\/cclm-2022-0770.","journal-title":"Clin Chem Lab Med"},{"key":"1513_CR50","doi-asserted-by":"publisher","unstructured":"Janelidze S, Barth\u00e9lemy NR, He Y, et al. Mitigating the Associations of Kidney Dysfunction With Blood Biomarkers of Alzheimer Disease by Using Phosphorylated Tau to Total Tau Ratios. JAMA Neurol. Published Online First. 2023. https:\/\/doi.org\/10.1001\/jamaneurol.2023.0199.","DOI":"10.1001\/jamaneurol.2023.0199"}],"updated-by":[{"DOI":"10.1186\/s13195-024-01538-0","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2024,7,27]],"date-time":"2024-07-27T00:00:00Z","timestamp":1722038400000}}],"container-title":["Alzheimer's Research &amp; Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13195-024-01513-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13195-024-01513-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13195-024-01513-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,28]],"date-time":"2024-07-28T02:02:23Z","timestamp":1722132143000},"score":1,"resource":{"primary":{"URL":"https:\/\/alzres.biomedcentral.com\/articles\/10.1186\/s13195-024-01513-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6,26]]},"references-count":50,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["1513"],"URL":"https:\/\/doi.org\/10.1186\/s13195-024-01513-9","relation":{},"ISSN":["1758-9193"],"issn-type":[{"value":"1758-9193","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,6,26]]},"assertion":[{"value":"8 December 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 June 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 June 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 July 2024","order":4,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":5,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":6,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1186\/s13195-024-01538-0","URL":"https:\/\/doi.org\/10.1186\/s13195-024-01538-0","order":7,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The ethics committee of Hospital Sant Pau approved all procedures included in this study following the standards for medical research in humans recommended by the Declaration of Helsinki. All participants or their legally authorised representative gave written informed consent before enrolment in the study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"All authors revised the manuscript for content and provided critical feedback.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Daniel Alcolea is employed by Hospital de la Santa Creu i Sant Pau and received research grants from Pla Estrat\u00e8gic de Recerca i Innovaci\u00f3 en Salut (PERIS SLT006\/17\/125), and from Instituto de Salud Carlos III (PI18\/00435 and INT19\/00016). He participated in advisory boards from Fujirebio-Europe and Roche Diagnostics and received speaker honoraria from Fujirebio-Europe, Roche Diagnostics, Nutricia, Zambon S.A.U., Esteve, and from Krka Farmac\u00e9utica S.L.Javier Arranz is employed by Biomedical Research Institute Sant Pau. He is funded by a \u201cRio Hortega\u201d research grant from the Institute of Health Carlos III. Declarations of interest: none.Nuole Zhu is employed by Biomedical Research Institute Sant Pau. He is funded by a \u201cRio Hortega\u201d research grant from the Institute of Health Carlos III. Declarations of interest: none.Sara Rubio-Guerra is employed by Hospital de la Santa Creu i Sant Pau. Declarations of interest: none.I\u00f1igo Rodr\u00edguez-Baz is employed by Biomedical Research Institute Sant Pau. He is funded by a \u201cRio Hortega\u201d research grant from the Institute of Health Carlos III. Declarations of interest: none.Rosa Ferrer is employed by Hospital de la Santa Creu i Sant Pau. Declarations of interest: none.Mar\u00eda Carmona-Iragui is employed by Hospital de la Santa Creu i Sant Pau. Declarations of interest: none.Isabel Barroeta is employed by Hospital de la Santa Creu i Sant Pau. Declarations of interest: none.Dr. Ill\u00e1n-Gala is a senior Atlantic Fellows for Equity in Brain Health at the Global Brain Health Institute (GBHI), and is supported with funding from GBHI, Alzheimer\u2019s Association, and Alzheimer\u2019s Society (GBHI ALZ UK-21\u2013720973 and AACSF-21\u2013850193). Dr Ill\u00e1n-Gala was also supported by the Juan Rod\u00e9s Contract (JR20\/0018) and Fondo de Investigaciones Sanitario, (PI21\/00791) from Instituto de Salud Carlos III.Ignacio Ill\u00e1n-Gala reported receiving personal fees from Nutricia, Esteve, UCB, and Neuraxpharm Spain outside the submitted work.Miguel Santos-Santos is employed by Hospital de la Santa Creu i Sant Pau. His research is supported by funding from the Spanish Institute of Health Carlos III (Juan Rod\u00e9s contract JR18-00018; Fondo de investigaci\u00f3n sanitaria grant PI19\/00882), the Alzheimer\u2019s Association clinician scientist fellowship (AACSF-22\u2013972945), and the National Institutes of Health (R01AG080470).Juan Fortea is employed by Hospital de la Santa Creu i Sant Pau and received research grants from Institute of Health Carlos III, National Institutes of Health, Fundaci\u00f3 La Marat\u00f3 de TV3, and Pla Estrat\u00e8gic de Recerca i Innovaci\u00f3 en Salut (PERIS). Dr. Fortea has served as a consultant for Novartis and Lundbeck, has received honoraria for lectures from Roche, NovoNordisk, Esteve and Biogen and served at advisory boards for AC Immune, Zambon and Lundbeck.Alberto Lle\u00f3 is employed by Hospital de la Santa Creu i Sant Pau and received research grants from CIBERNED, Institute of Health Carlos III, Generalitat de Catalunya (PERIS and AGAUR) and Fundaci\u00f3n Tatiana and BBVA. He participated in advisory boards from Biogen, Eisai, Fujirebio-Europe, Novartis, NovoNordisk, Nutricia, Otsuka Pharmaceutical, and Zamb\u00f3n, and received speaker honoraria from Lilly, Biogen, KRKA and Zambon.Mireia Tondo is employed by Hospital de la Santa Creu i Sant Pau and has received research grants from Instituto de Salud Carlos III (PI18\/00164; PI21\/00140) and has served as consultant in Araclon.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"139"}}